Patents by Inventor Brian L. Hodous

Brian L. Hodous has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions useful for treating disorders related to KIT
    Patent number: 11827642
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: November 28, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20230129944
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 27, 2023
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
    Publication number: 20220315585
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: May 29, 2020
    Publication date: October 6, 2022
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian L. Hodous, Joseph L. Kim, Josh Waetzig, Brett Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
    Patent number: 11236086
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 1, 2022
    Assignee: Blueprint Medicines Corporation
    Inventors: Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20210347756
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 11, 2021
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20210284645
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: October 14, 2020
    Publication date: September 16, 2021
    Applicants: Blueprint Medicines Corporation, Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
    Patent number: 11040979
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 22, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10875837
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
    Publication number: 20200331908
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: October 18, 2018
    Publication date: October 22, 2020
    Inventors: Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20200109127
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 9, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • PYRROLO[1,2-B]PYRIDAZINE COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDGFR
    Publication number: 20200024280
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 23, 2020
    Applicant: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20190359682
    Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 28, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil BIFULCO, JR., Natasja BROOIJMANS, Brian L. HODOUS, Joseph L. KIM, Chandrasekhar V. MIDUTURU
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10413562
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 17, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20190144454
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: May 7, 2018
    Publication date: May 16, 2019
    Inventors: Brian L. HODOUS, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT AND PDGFR
    Publication number: 20190119280
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
    Type: Application
    Filed: May 7, 2018
    Publication date: April 25, 2019
    Inventors: Brian L. HODOUS, Kevin J. Wilson, Yulian Zhang
  • Inhibitors of activin receptor-like kinase
    Patent number: 10233186
    Abstract: Described herein are compounds, such as compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: March 19, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Mark Cronin, Paul E. Fleming, Brian L. Hodous, Joseph L. Kim, Brett Williams, Douglas Wilson, Kevin J. Wilson
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10221154
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 5, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20180362613
    Abstract: Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
    Type: Application
    Filed: January 10, 2018
    Publication date: December 20, 2018
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: NEIL BIFULCO, JR., NATASJA BROOIJMANS, BRIAN L. HODOUS, JOSEPH L. KIM, CHANDRASEKHAR V. MIDUTURU
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20180243324
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: May 3, 2018
    Publication date: August 30, 2018
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 10016448
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 10, 2018
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger